What Changed

Radiopharm Theranostics said data on RAD101 were selected for a late-breaking oral presentation, and the company also disclosed an FDA meeting date of October 1st.

A low-angle photograph of stacked clinical trial documents and research papers with visible texture, stamps and handwritten annotations, lit by soft directional light.
Radiopharm's RAD101 Wins Late-Breaking Slot at SNO26

“Having these data selected for a late-breaking oral presentation at SNO26 is a meaningful recognition of the potential clinical importance of RAD101.”

Riccardo Canevari, CEO, Radiopharm Theranostics

Highlights

  • RAD101 targets fatty acid synthase (FASN).
  • RAD101 holds Fast Track Designation from the FDA.
  • The Phase 2b clinical trial of RAD101 lists sensitivity and specificity as its secondary endpoints.
  • Radiopharm Theranostics has a partnership with Siemens Healthineers.

About RAD101

RAD101 targets fatty acid synthase (FASN), and the compound holds Fast Track Designation from the FDA.

Trial Design

The Phase 2b clinical trial of RAD101 lists sensitivity and specificity as its secondary endpoints.

Partnerships and Leadership

Radiopharm Theranostics has a partnership with Siemens Healthineers.

Paul Hopper serves as the company's Executive Chairman.

What To Watch Next

The FDA meeting is scheduled for October 1st, and the late-breaking oral presentation will feature the RAD101 data described above.